Indications and Purposes
| 1 Indications And Usage Tibsovo Is An Isocitrate Dehydrogenase-1 (Idh1) Inhibitor Indicated For The Treatment Of Acute Myeloid Leukemia (Aml) With A Susceptible Idh1 Mutation As Detected By An Fda-Approved Test In: Adult Patients With Newly-Diagnosed Aml Who Are ≥ 75 Years Old Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. ( 1.1 ). Adult Patients With Relapsed Or Refractory Aml ( 1.2 ). 1.1 Newly-Diagnosed Acute Myeloid Leukemia Tibsovo Is Indicated For The Treatment Of Newly-Diagnosed Acute Myeloid Leukemia (Aml) With A Susceptible Isocitrate Dehydrogenase-1 (Idh1) Mutation As Detected By An Fda-Approved Test In Adult Patients Who Are ≥ 75 Years Old Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy [See Dosage And Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ) And Clinical Studies ( 14.1 )]. 1.2 Relapsed Or Refractory Acute Myeloid Leukemia Tibsovo Is Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia (Aml) With A Susceptible Isocitrate Dehydrogenase-1 (Idh1) Mutation As Detected By An Fda-Approved Test [See Dosage And Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ) And Clinical Studies ( 14.2 )]. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Ivosidenib |